Transgene

Transgene Net Margin

The Net Profit Margin of Transgene (TNG.PA) as of Sep 30, 2026 is -558.64 %. In the previous year, Net Profit Margin was -292.48 % — a change of 91.00% (lower).

Net Margin

-558.64 %

YoY

91.00%

Last updated:

Net Profit Margin of Transgene is 2026 -558.64 % . Net Profit Margin of Transgene was 2025 -292.48 % . It decreases by 91.00% lower compared to the previous year.

Transgene's net margin stands at -558.6%, down from -184.4% several years earlier.

The Transgene Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
-432.80 EUR
Jan 1, 2018
113.30 EUR
Jan 1, 2019
-141.43 EUR
Jan 1, 2020
-184.43 EUR
Jan 1, 2021
-114.82 EUR
Jan 1, 2022
-327.97 EUR
Jan 1, 2023
-292.48 EUR
Jan 1, 2024
-558.64 EUR
The Transgene Net Margin history
YEARNet MarginYoY
-558.64 %+91.00%
-292.48 %-10.82%
-327.97 %+185.63%
-114.82 %-37.74%
-184.43 %+30.41%
-141.43 %-224.83%
113.30 %-126.18%
-432.80 %+49.86%
-288.81 %-40.43%
-484.83 %+10.82%
-437.48 %+15,966.14%
-2.72 %-17.68%
-3.31 %+9.55%
-3.02 %+24.50%
-2.43 %+4.37%
-2.32 %+80.09%
-1.29 %+554.98%
-0.20 %-95.04%
-3.97 %-21.52%
-5.06 %—
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Net Profit Margin of Transgene is -558.64 % in 2026.

Net Profit Margin of Transgene changed from -292.48 % to -558.64 %, representing a 91.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Transgene since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Transgene

All Key Metrics — Transgene